Jacob G Dubroff1, Robert K Doot2, Mary Falcone3, Robert A Schnoll3, Riju Ray4, Rachel F Tyndale5, Arthur L Brody6, Catherine Hou2, Alexander Schmitz2, Caryn Lerman3. 1. Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania jacob.dubroff@uphs.upenn.edu. 2. Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Global Medical Affairs, GlaxoSmithKline, Brussels, Belgium. 5. Department of Pharmacology and Toxicology, and Department of Psychiatry, CAMH, University of Toronto, Toronto, Canada. 6. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California; and Department of Psychiatry, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, California.
Abstract
UNLABELLED: The nicotine metabolite ratio (NMR), a stable measure of hepatic nicotine metabolism via the CYP2A6 pathway and total nicotine clearance, is a predictive biomarker of response to nicotine replacement therapy, with increased quit rates in slower metabolizers. Nicotine binds directly to nicotinic acetylcholine receptors (nAChRs) to exert its psychoactive effects. This study examined the relationship between NMR and nAChR (α4β2* subtype) availability using PET imaging of the radiotracer 2-(18)F-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-(18)F-FA-85380, or 2-(18)F-FA). METHODS: Twenty-four smokers-12 slow metabolizers (NMR < 0.26) and 12 normal metabolizers (NMR ≥ 0.26)-underwent 2-(18)F-FA-PET brain imaging after overnight nicotine abstinence (18 h before scanning), using a validated bolus-plus-infusion protocol. Availability of nAChRs was compared between NMR groups in a priori volumes of interest, with total distribution volume (VT/fP) being the measure of nAChR availability. Cravings to smoke were assessed before and after the scans. RESULTS: Thalamic nAChR α4β2* availability was significantly reduced in slow nicotine metabolizers (P = 0.04). Slow metabolizers exhibited greater reductions in cravings after scanning than normal metabolizers; however, craving was unrelated to nAChR availability. CONCLUSION: The rate of nicotine metabolism is associated with thalamic nAChR availability. Additional studies could examine whether altered nAChR availability underlies the differences in treatment response between slow and normal metabolizers of nicotine.
UNLABELLED: The nicotine metabolite ratio (NMR), a stable measure of hepatic nicotine metabolism via the CYP2A6 pathway and total nicotine clearance, is a predictive biomarker of response to nicotine replacement therapy, with increased quit rates in slower metabolizers. Nicotine binds directly to nicotinic acetylcholine receptors (nAChRs) to exert its psychoactive effects. This study examined the relationship between NMR and nAChR (α4β2* subtype) availability using PET imaging of the radiotracer 2-(18)F-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-(18)F-FA-85380, or 2-(18)F-FA). METHODS: Twenty-four smokers-12 slow metabolizers (NMR < 0.26) and 12 normal metabolizers (NMR ≥ 0.26)-underwent 2-(18)F-FA-PET brain imaging after overnight nicotine abstinence (18 h before scanning), using a validated bolus-plus-infusion protocol. Availability of nAChRs was compared between NMR groups in a priori volumes of interest, with total distribution volume (VT/fP) being the measure of nAChR availability. Cravings to smoke were assessed before and after the scans. RESULTS: Thalamic nAChR α4β2* availability was significantly reduced in slow nicotine metabolizers (P = 0.04). Slow metabolizers exhibited greater reductions in cravings after scanning than normal metabolizers; however, craving was unrelated to nAChR availability. CONCLUSION: The rate of nicotine metabolism is associated with thalamic nAChR availability. Additional studies could examine whether altered nAChR availability underlies the differences in treatment response between slow and normal metabolizers of nicotine.
Authors: Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Trinh Luu; Meaghan Neary; Lidia Liang; Jennifer Shieh; Catherine A Sugar; Jed E Rose; Mark A Mandelkern Journal: JAMA Psychiatry Date: 2014-07-01 Impact factor: 21.596
Authors: Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Maggie Kozman; Jonathan Phuong; Meaghan Neary; Trinh Luu; Mark A Mandelkern Journal: Neuropsychopharmacology Date: 2013-02-21 Impact factor: 7.853
Authors: Michael J Marks; Tristan D McClure-Begley; Paul Whiteaker; Outi Salminen; Robert W B Brown; John Cooper; Allan C Collins; Jon M Lindstrom Journal: J Pharmacol Exp Ther Date: 2011-01-12 Impact factor: 4.030
Authors: Bernard Le Foll; Svetlana I Chefer; Alane S Kimes; Dean Shumway; Elliot A Stein; Alexey G Mukhin; Steven R Goldberg Journal: Biol Psychiatry Date: 2008-12-18 Impact factor: 13.382
Authors: Robert A Schnoll; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Karam Mounzer; Rachel F Tyndale; Jessica Weisbrot; Miles Meline; Ronald G Collman; Rebecca L Ashare Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731
Authors: Rebecca L Ashare; Morgan Thompson; Frank Leone; David Metzger; Robert Gross; Karam Mounzer; Rachel F Tyndale; Caryn Lerman; Martin C Mahoney; Paul Cinciripini; Tony P George; Ronald G Collman; Robert Schnoll Journal: AIDS Date: 2019-05-01 Impact factor: 4.177
Authors: Simon R Cherry; Terry Jones; Joel S Karp; Jinyi Qi; William W Moses; Ramsey D Badawi Journal: J Nucl Med Date: 2017-09-21 Impact factor: 10.057
Authors: Walter Roberts; Phillip L Marotta; Terril L Verplaetse; MacKenzie R Peltier; Catherine Burke; Vijay A Ramchandani; Sherry A McKee Journal: Drug Alcohol Depend Date: 2020-08-05 Impact factor: 4.492
Authors: Brian V Fix; Richard J O'Connor; Neal Benowitz; Bryan W Heckman; K Michael Cummings; Geoffrey T Fong; James F Thrasher Journal: Nicotine Tob Res Date: 2017-09-01 Impact factor: 4.244